Carga Viral y Recuento de Linfocitos T Cd4: Referencias

REFERENCIAS

1. Ministerio de la Protección Social. República de Colombia. Listado de precios promedio y unidades en la cadena de comercialización de medicamentos. Enero a Diciembre de 2010.
2. Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro P, et al. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med. 2012 Sep. 4; 157(5):325-35.
3. Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, et al. Highly active
antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: The HIV Netherlands-Australia-Thailand Research Collaboration 001.4 Study. J Acquir Immune Defic Syndr. 2005 Aug 15; 39(5):523-9.
4. Buskin S, Zhang S, Thibault C. Prevalence of and viral outcomes associated with primary HIV-1 drug resistance. Open AIDS J. 2012; 6:181-7.
5. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 protocol virology substudy team. Ann Intern Med. 1997 Jun 15; 126(12):929-38.
6. lsa SE, Gwamzhi LN, Akolo C, Giyan J. A prospective cohort study of immunologic and virologic outcomes in patients with HIV/AIDS and hepatitis virus co-infection in Jos, Nigeria. Niger J Med. 2010 Jul-Sep.; 19(3):279-85.
7. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997 Jun 15; 126(12):946-54.
8. Mellors JW, Rinaldo CR, Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996 May 24; 272(5265):1167-70.
9. Diaz M, Tobar C, Avila G. Correlation immune CD4- CD8 and viral load in HIV infection, Colombia. Infectio. 2012; 5(2):113.
10. Localidad de Kennedy. Ficha básica secretaría distrital de cultura, recreación y deportes. Observatorio de culturas. Bogotá: Noviembre 2008. [Internet]. Available from: https://www.hospitaloccidentekennedy.gov. co/ver_contenidos.php?id=32&menu=0.
11. Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, et al. Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haití. J Int AIDS Soc. 2012 Jun 14; 15(2):17375.
12. Wojewoda CM, Spahlinger T, Harmon ML, Schnellinger B, Li Q, Dejelo C, et al. Comparison of roche cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 (CAP/CTM v2.0) with other real-time PCR assays in HIV-1 monitoring and follow-up of low-level viral loads. J Virol Methods. 2012 Oct 22
13. Yehia BR, Fleishman JA, Metlay JP, Moore RD, Gebo KA. Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy. JAMA. 2012 Jul 25; 308(4):339-42.
14. Passaes CP, Guimaraes ML, Cardoso SW, Pilotto JH, Veloso V, Grinsztejn B, et al. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: A follow-up study. J Med Virol.
2012 Dec; 84(12):1869-75
15. Davies MA, Boulle A, Technau K, Eley B, Moultrie H, Rabie H, et al. The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure. Trop Med Int Health. 2012 Sep 14.
16. Hamers RL, Sawyer AW, Tuohy M, Stevens WS, Rinke de Wit TF, Hill AM, et al. Cost-effectiveness oflaboratory monitoring for management of HIV treatment in sub-saharan África: A model-based analysis. AIDS. 2012 Aug 24; 26(13):1663-72.
17. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost-effectiveness of HIV treatment in resource-poor settings–the case of Cote d’Ivoire. N Engl J Med. 2006 Sep 14; 355(11):1141-53.
18. Lacey L, Hopkinson PK, Montaner J, Leblanc F, Gill MJ. An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection. Canadian perspective. Pharmacoeconomics. 1999; 15 Suppl 1:55-66.
19. Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, et al. Efavirenz versus nevirapine-based initial treatment of HIV infection: Clinical and virological outcomes in southern African adults. AIDS. 2008 Oct 18; 22(16):2117-25.
20. Lado F. Between CD4 and viral load in patients infected with human immunodeficiency virus TB. . 2001 An. Med. Interna; 18(12):624-8.

Fecha de recibido: Noviembre 8, 2012
Fecha de aceptado: Febrero 4, 2013
Dirección para correspondencia:
Elkin Lemos Fundación para el desarrollo y apoyo en salud internacional (FUDASAI)
Carrera 82 A # 6-16 Interior 6 AP 1023, Bogotá, Colombia.
[email protected]

DÉJANOS TU COMENTARIO

DEJA UNA RESPUESTA

Por favor ingrese su comentario!